Effect of GDMT optimization on KDIGO risk categories in HFrEF

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Noel Panagiotides

Medical University of Vienna, Vienna (Austria)

5 More presentations in this session

Presentation thumbnail

Treatment patterns of heart failure patients with reduced or mildly reduced ejection fraction on dapagliflozin: baseline data from the 3rd interim analysis of two EVOLUTION-HF DEallEF study cohorts

Professor M. Paul (Muenster, DE)

Presentation thumbnail

Intravenous iron therapy in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Doctor R. Ali (Pembroke Pines, US)

Presentation thumbnail

Real-word elegibiliy and tolerability of vericiguat in HFrEF: data from a multicenter registry

Associate Professor S. Nodari (Brescia, IT)

Presentation thumbnail

Comparison of the 2016 and 2025 ASE/EACVI Guidelines on HFpEF

Miss W. Hu (Hangzhou, CN)

Presentation thumbnail

Bridging inequity in HFpEF care: pilot project experience informing the design and implementation of a multidisciplinary blueprint

Doctor M. Lee (Glasgow, GB)

Access the full session

Session thumbnail

Challenges and solutions in guideline-directed therapy in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources